EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing ...

Creative Biolabs has expanded its complement testing capabilities to help researchers overcome challenges in complement drug development through comprehensive complement activity assays, CH50 ...

The update is a blow for an asset that Sanofi lists among its key mid- and late-stage programs. (Jwala Kotesh/NurPhoto/Getty Images) Sanofi has stopped a phase 3 autoimmune clinical trial early after ...

Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its primary and a key secondary endpoint in the phase III NIMBLE trial of ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...

Please provide your email address to receive an email when new articles are posted on . CTx001 is an investigational adeno-associated virus-based therapy for geographic atrophy. Patient dosing in the ...

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced positive ...